Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct-Dec;47(4):479-484.
doi: 10.12865/CHSJ.47.04.01. Epub 2021 Dec 31.

Knowledge and Willingness to Accept Vaccine Against SARS-CoV-2 Among Undergraduate Medical Students in Delhi, India

Aumkar K Shah  1 , Roy A Daniel  1 , Yadlapalli S Kusuma  1
Affiliations

Knowledge and Willingness to Accept Vaccine Against SARS-CoV-2 Among Undergraduate Medical Students in Delhi, India

Aumkar K Shah et al. Curr Health Sci J. 2021 Oct-Dec.

Abstract

Vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the most desired solution to combat COVID-19. Understanding the willingness to accept vaccines is essential to make appropriate strategies for the vaccination programme's success. There was a lack of published literature in India among medical students. Hence, we conducted this online, cross-sectional study to assess the knowledge and willingness to accept COVID-19 vaccines among undergraduate medical students of a medical school in Delhi. A complete enumeration of all the undergraduate medical students was done. All the students were invited to participate in this online survey. The questionnaire through Google forms was shared through email and WhatsApp. The questionnaire contained questions on the socio-demographic details, questions related to the knowledge and perceptions about COVID-19 vaccines, willingness to accept the vaccine and vaccination status of the participant. Descriptive and multiple logistic regression analyses were carried out. Out of 320 students contacted, 298 consented to participate in the survey, and 274 participants (85%) completed the questionnaire. Three-fourths of the participants were male; the mean age of the study participants was 19.6 years. Only 70.4% were willing to accept the vaccine. Those who perceived COVID-19 vaccines as safe (AOR=3.946; 95% CI: 1.946 to 7.912); and effective (AOR=2.079; 95% CI: 1.054 to 4.101); and who has knowledge about the vaccines (AOR=2.206; 95% CI: 1.186 to 4.104) were more likely to accept the vaccine. There is a need for enhancing the knowledge on vaccines, and their safety and effectiveness to promote the vaccine acceptance.

Keywords: COVID-19; India; SARS-CoV-2; medical students; vaccine acceptance; vaccine hesitancy.

PubMed Disclaimer

Conflict of interest statement

None to declare.

References

    1. Li H, Liu SM, Yu XH, Tang SL, Tang CK. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951–105951. - PMC - PubMed
    1. Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS. Coronavirus disease 2019-COVID-19. Clinical microbiology reviews. 2020;33(4):e00028–e00028. - PMC - PubMed
    1. Draft landscape and tracker of COVID-19 candidate vaccines. Geneva: World Health Organization; 2021. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-cand...[Accessed 19.07.2021]
    1. Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®. Hyderabad: Bharat Biotech: 21 July 2021. Available from: https://www.bharatbiotech.com/images/press/covaxin-phase3-clinical-trial...[Accessed 21.01.2021]
    1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford CVTG. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. - PMC - PubMed

LinkOut - more resources